Karyopharm Therapeutics reported $8.01M in Interest Expense on Debt for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Expense On Debt Change
Abbott ABT:US $ 123M 11M
Amgen AMGN:US $ 296M 15M
Biocryst Pharmaceuticals BCRX:US $ 14.12M 0.62M
Bristol Myers Squibb BMY:US $ 328M 2M
Eli Lilly And LLY:US $ 83.6M 3.3M
Epizyme EPZM:US $ 445K 52K
Karyopharm Therapeutics KPTI:US $ 8.01M 3.01M
Nektar Therapeutics NKTR:US $ 12.8M 0.29M
Novartis NOVN:VX 202M 1000K
Novartis NVS:US $ 202M 1M
Pfizer PFE:US $ 325M 9M
Regeneron Pharmaceuticals REGN:US $ 14.2M 0.2M
Tg Therapeutics TGTX:US $ 1.04M 0.58M
YTE INCY:US $ 0.44M 0.08M